Acute Myocardial Infarction – Immediate Management in the Emergency Department

Diagnostic Evaluation

• Obtain a 12‑lead ECG within 10 minutes of patient arrival and initiate continuous cardiac monitoring with defibrillator capability; give aspirin (75–100 mg oral or IV) immediately unless contraindicated. – European Society of Cardiology (ESC) guideline, Class I, Level A. 1
• Avoid routine supplemental oxygen unless peripheral oxygen saturation is < 90 %. – ESC guideline, Class III (Harm), Level B. 1

Initial Pharmacologic Therapy

Antiplatelet Therapy

• Administer aspirin 75–100 mg as soon as possible to all patients without contraindications. – ESC guideline, Class I, Level A. 1
• Give a loading dose of a potent P2Y12 inhibitor (prasugrel or ticagrelor preferred; clopidogrel if the former are unavailable or contraindicated) before or at the time of PCI. – ESC guideline, Class I, Level A. 1

Analgesia

• Use IV morphine cautiously; observational data show higher rates of death (5.5 % vs 4.7 %), myocardial infarction (3.8 % vs 3.0 %), and the composite of death/MI (8.5 % vs 7.1 %) compared with no morphine. – ESC guideline, Class IIb, Level B. 2

Reperfusion Strategies

Primary PCI (STEMI ≤ 12 h)

• Primary percutaneous coronary intervention (PCI) is the preferred reperfusion method when it can be performed without delay. – ESC guideline, Class I, Level A. 1
• Transfer the patient directly to the catheterisation laboratory, bypassing emergency‑department holding areas. – ESC guideline, Class I, Level A. 1
• Use unfractionated heparin or enoxaparin as anticoagulation during primary PCI. – ESC guideline, Class I, Level A. 1
• Do not use fondaparinux as anticoagulation for primary PCI. – ESC guideline, Class III (Harm), Level A. 1

Fibrinolysis (when primary PCI not timely)

• If primary PCI cannot be performed promptly, give fibrinolytic therapy within 12 hours of symptom onset provided no contraindications exist. – ESC guideline, Class I, Level A. 1
• Select a fibrin‑specific agent (tenecteplase, alteplase, or reteplase). – ESC guideline, Class I, Level A. 1
• Add aspirin and clopidogrel to the fibrinolytic regimen. – ESC guideline, Class I, Level A. 1
• Prefer enoxaparin (IV bolus followed by subcutaneous dosing) over unfractionated heparin for anticoagulation; weight‑adjusted UFH bolus + infusion is an alternative. – ESC guideline, Class I, Level A. 1
• Immediately transfer the patient to a PCI‑capable centre after fibrinolysis. – ESC guideline, Class I, Level A. 1

Post‑Fibrinolysis Management

• Perform emergency angiography and PCI without delay if the patient develops heart failure or cardiogenic shock. – ESC guideline, Class I, Level A. 1
• If fibrinolysis fails (≤ 50 % ST‑segment resolution at 60–90 min) or the patient becomes hemodynamically/electrically unstable, initiate rescue PCI immediately. – ESC guideline, Class I, Level A. 1
• In patients with successful fibrinolysis, schedule angiography and PCI of the infarct‑related artery between 2 and 24 hours. – ESC guideline, Class IIa, Level B. 1

Special Situations

• In patients who have a cardiac arrest and subsequently show STEMI on ECG, pursue a primary PCI strategy. – ESC guideline, Class I, Level A. 1
• Start targeted temperature management early in resuscitated patients who remain unresponsive. – ESC guideline, Class I, Level B. 1
• Avoid pre‑hospital cooling with large volumes of cold IV fluid immediately after return of spontaneous circulation. – ESC guideline, Class III (Harm), Level B. 1

Pitfalls to Avoid

• Do not postpone reperfusion therapy for routine echocardiography or other non‑essential testing in clear STEMI cases. – ESC guideline, Class III (Harm), Level A. 1
• Do not perform routine PCI of an occluded infarct‑related artery beyond 48 hours after STEMI onset in asymptomatic patients. – ESC guideline, Class III (Harm), Level A. 1
• Do not give IV beta‑blockers to patients with hypotension, acute heart failure, high‑grade AV block, or severe bradycardia. – ESC guideline, Class III (Harm), Level B. 3
• Do not use fondaparinux as anticoagulation for primary PCI. – ESC guideline, Class III (Harm), Level A. 1

Early In‑Hospital Therapies

• Start high‑intensity statin therapy as early as possible unless contraindicated. – ESC guideline, Class I, Level A. 3
• Begin an ACE inhibitor within the first 24 hours in patients with heart failure, left‑ventricular systolic dysfunction, diabetes, or an anterior infarct. – ESC guideline, Class I, Level A. 3
• Initiate oral beta‑blocker therapy in patients with heart failure and/or left‑ventricular ejection fraction < 40 % unless contraindicated. – ESC guideline, Class I, Level A. 3
• Continue dual antiplatelet therapy (aspirin + ticagrelor or prasugrel) for 12 months unless the bleeding risk is excessive. – ESC guideline, Class I, Level A. 1

Acute Management of Myocardial Ischemia Identified on ECG

Initial Assessment and Immediate Therapy

• Obtain a 12‑lead ECG within 10 minutes of patient arrival, start continuous cardiac monitoring with defibrillator capability, and give aspirin 75–100 mg orally or intravenously unless contraindicated (European Society of Cardiology guideline) 4.

Reperfusion Strategies for STEMI

Primary PCI

• Primary percutaneous coronary intervention (PCI) is the preferred reperfusion method when the first‑medical‑contact‑to‑device time is ≤ 90 minutes for direct presenters or ≤ 120 minutes for transferred patients (ESC guideline) 4.
• Activate the cardiac catheterisation laboratory immediately and transport the patient directly to the laboratory, bypassing the emergency department and intensive‑care unit (ESC guideline) 4.
• Give a potent P2Y12 inhibitor (prasugrel or ticagrelor preferred; clopidogrel if unavailable or contraindicated) before or at the time of PCI and continue for 12 months unless bleeding risk is high (ESC guideline) 4.
• Use unfractionated heparin or enoxaparin as anticoagulation during primary PCI; fondaparinux must not be used (ESC guideline) 4.

When Primary PCI Is Not Feasible Within Recommended Times

• If primary PCI cannot be performed within 120 minutes of first medical contact, administer fibrinolytic therapy within 12 hours of symptom onset, preferably in the pre‑hospital setting (ESC guideline) 4.
• Choose a fibrin‑specific agent such as tenecteplase, alteplase, or reteplase (ESC guideline) 4.
• Add aspirin and clopidogrel to the fibrinolytic regimen (ESC guideline) 4.
• Prefer enoxaparin (intravenous bolus followed by subcutaneous dosing) for anticoagulation after fibrinolysis; a weight‑adjusted unfractionated heparin bolus plus infusion is an alternative (ESC guideline) 4.
• Arrange immediate transfer to a PCI‑capable centre after fibrinolysis for all patients (ESC guideline) 4.

Post‑Fibrinolysis Management

• Perform emergency angiography and PCI without delay if the patient develops heart failure, cardiogenic shock, haemodynamic instability, or electrical instability (ESC guideline) 4.
• If fibrinolysis fails (≤ 50 % ST‑segment resolution at 60–90 minutes), proceed to rescue PCI immediately (ESC guideline) 4.
• In patients with successful fibrinolysis who remain stable, schedule angiography and PCI of the infarct‑related artery between 2 and 24 hours after therapy (ESC guideline) 4.

Management of Non‑ST‑Segment Elevation ACS (NSTE‑ACS)

• Patients with transient ST‑segment depression, T‑wave inversion, flat or pseudo‑normalised T waves should be risk‑stratified using high‑sensitivity cardiac troponin levels together with clinical features (ESC guideline) 5.
• Immediate coronary angiography and revascularisation are indicated for those with ongoing myocardial ischaemia manifested by recurrent chest pain, marked ST‑segment depression, heart failure, haemodynamic or electrical instability (ESC guideline) 5.
• Administer aspirin 75–100 mg and a potent P2Y12 inhibitor (ticagrelor or prasugrel preferred; clopidogrel if unavailable) (ESC guideline) 5.

Adjunctive Pharmacologic and Supportive Measures

• Routine supplemental oxygen should be avoided unless peripheral oxygen saturation is < 90 % (ESC guideline) 4.
• Initiate high‑intensity statin therapy as early as possible and continue long‑term unless contraindicated (ESC guideline) 4.
• Start an ACE inhibitor within the first 24 hours in patients with heart failure, left‑ventricular ejection fraction < 40 %, diabetes, or anterior infarction (ESC guideline) 4.
• Begin oral beta‑blocker therapy in patients with heart failure and/or left‑ventricular ejection fraction < 40 % unless contraindicated; intravenous beta‑blockers must be avoided in the presence of hypotension, acute heart failure, high‑grade atrioventricular block, or severe bradycardia (ESC guideline) 4.

Special Clinical Scenarios

• In patients who have been resuscitated from cardiac arrest and show STEMI on ECG, a primary PCI strategy should be pursued (ESC guideline) 4.
• Early targeted temperature management is recommended for resuscitated patients who remain unresponsive (ESC guideline) 4.
• Pre‑hospital cooling with large volumes of cold intravenous fluid should not be used immediately after return of spontaneous circulation (ESC guideline) 4.

Pitfalls to Avoid

• Do not postpone reperfusion therapy for routine echocardiography or other non‑essential testing in clear STEMI cases (ESC guideline) 4.
• Routine PCI of an occluded infarct‑related artery beyond 48 hours after STEMI onset should not be performed in asymptomatic patients (ESC guideline) 4.
• Fondaparinux must not be used as anticoagulation for primary PCI (ESC guideline) 4.
• Intravenous beta‑blockers must not be given to patients with hypotension, acute heart failure, high‑grade AV block, or severe bradycardia (ESC guideline) 4.

Management of STEMI in Patients with Incidental Manubrial Mass

Immediate Reperfusion Priorities

• Proceed immediately with standard STEMI reperfusion (primary PCI or fibrinolysis) without delaying for evaluation of the manubrial mass; the acute MI takes absolute priority. – European Society of Cardiology (ESC) guideline, Class I, Level A. [6][7]
• Obtain a 12‑lead ECG within 10 minutes of arrival and give aspirin 75–100 mg orally or IV immediately unless contraindicated. – ESC guideline, Class I, Level A. 6
• If primary PCI can be performed without delay, it is the preferred reperfusion method and should be achieved ideally within 90–120 minutes of first medical contact. – ESC guideline, Class I, Level A. [6][7]
• Transfer the patient directly to the catheterisation laboratory, bypassing the emergency department. – ESC guideline, Class I, Level A. [6][7]

Antithrombotic and Anticoagulation Strategies (Primary PCI)

• Give a potent P2Y12 inhibitor (prasugrel or ticagrelor preferred; clopidogrel if unavailable) before or at the time of PCI and continue for 12 months. – ESC guideline, Class I, Level A. [6][7]
• Use unfractionated heparin or enoxaparin for anticoagulation during primary PCI; fondaparinux is contraindicated. – ESC guideline, Class I, Level A. [6][7]

Fibrinolysis When Primary PCI Is Not Immediately Available

• Administer fibrinolytic therapy within 12 hours of symptom onset if primary PCI cannot be performed within 120 minutes of STEMI diagnosis. – ESC guideline, Class I, Level A. [6][7]8
• Select a fibrin‑specific agent (tenecteplase, alteplase, or reteplase). – ESC guideline, Class I, Level A. [7][8]
• Add aspirin and clopidogrel to the fibrinolytic regimen. – ESC guideline, Class I, Level A. [7][8]
• Use enoxaparin (IV bolus followed by subcutaneous dosing) for anticoagulation; weight‑adjusted unfractionated heparin is an alternative. – ESC guideline, Class I, Level A. [7][8]
• Transfer the patient immediately to a PCI‑capable centre after fibrinolysis. – ESC guideline, Class I, Level A. [7][8]

Access Site and Bleeding‑Risk Considerations Related to the Manubrial Mass

• If the mass is known to be a benign bone lesion, lipoma, or other low‑risk entity, proceed with standard antithrombotic therapy without modification. – American Heart Association (AHA) guideline, Class I, Level A. [9][6]
• If the mass is unknown or potentially high‑risk for bleeding (e.g., suspected hemangioma or metastatic lesion), still proceed with reperfusion but preferentially use radial arterial access to minimise access‑site complications. – ESC guideline, Class I, Level A. 6
• Routine radial access is already the standard of care during primary PCI and provides lower bleeding risk irrespective of the manubrial mass. – ESC guideline, Class I, Level A. 6

Contra‑indications and Pitfalls

• Absolute contraindications to fibrinolysis include prior intracranial haemorrhage, structural cerebrovascular lesion, malignant intracranial neoplasm, ischemic stroke within 3 months, suspected aortic dissection, active bleeding or bleeding diathesis, and significant closed‑head or facial trauma within 3 months. – AHA guideline, Class I, Level A. 9
• A manubrial mass alone is not an absolute contraindication to fibrinolysis unless there is active bleeding from the mass or documented high haemorrhage risk (e.g., known vascular tumour with prior bleeding). – AHA & ESC guidelines, Class I, Level A. [9][8]
• If fibrinolysis is contraindicated because of bleeding risk from the mass, primary PCI becomes the sole reperfusion option and must be pursued emergently. – ESC guideline, Class I, Level A. [6][7]
• Do not postpone reperfusion therapy to obtain CT imaging of the manubrial mass; STEMI management has absolute priority. – ESC guideline, Class I, Level A. 6
• Do not withhold aspirin or P2Y12 inhibitors solely because of an uncharacterised mass without documented active bleeding. – ESC guideline, Class I, Level A. [6][7]
• Do not delay transfer to a PCI‑capable centre for additional diagnostic work‑up of the mass. – ESC guideline, Class I, Level A. [6][7]
• Do not use fondaparinux as anticoagulation for primary PCI, regardless of bleeding concerns. – ESC guideline, Class I, Level A. [6][7]

Post‑Reperfusion Evaluation of the Manubrial Mass

• Defer imaging and formal evaluation of the manubrial mass until after successful reperfusion and haemodynamic stabilisation (typically after 24 hours of monitoring). – ESC guideline, Class IIa, Level B. 6
• Routine transthoracic echocardiography during hospitalisation is indicated to assess left‑ventricular function and complications; incidental visualisation of anterior mediastinal structures may occur but is not intended for mass assessment. – ESC guideline, Class I, Level B. 7
• If further characterisation of the mass is required, perform CT or MRI after the acute STEMI phase, preferably before discharge or during early outpatient follow‑up. – ESC guideline, Class IIa, Level B. 6

Adjunctive Therapies

• Initiate high‑intensity statin therapy as early as possible unless contraindicated. – AHA guideline, Class I, Level A. 9
• Continue dual antiplatelet therapy (aspirin plus ticagrelor or prasugrel) for 12 months unless bleeding risk is excessive. – ESC guideline, Class I, Level A. [6][7]

ESC Guidelines for the Management of Acute Myocardial Infarction

Immediate Diagnostic and Supportive Measures

• Obtain a 12‑lead ECG within 10 minutes of arrival and start continuous cardiac monitoring with defibrillator capability (Class I, Level A) 10.
• Give aspirin 75–100 mg orally or intravenously immediately unless contraindicated (Class I, Level A) 10.
• Reserve supplemental oxygen for patients with SpO₂ < 90 %; routine oxygen does not improve outcomes and may be harmful (Class III, Level A) 10.

Reperfusion Strategy

Primary Percutaneous Coronary Intervention (PCI) – Preferred When Feasible

• Primary PCI is the default reperfusion method when it can be performed without delay (Class I, Level A) 10.
• Bypass the emergency department or ICU and transfer patients directly to the catheterisation laboratory to minimise door‑to‑balloon time (Class I, Level A) 10.
• Administer a potent P2Y12 inhibitor (prasugrel or ticagrelor preferred; clopidogrel only if the former are unavailable) before or at the time of PCI and continue for 12 months unless bleeding risk is high (Class I, Level A) 10.
• Use unfractionated heparin or enoxaparin for anticoagulation during primary PCI (Class I, Level A) 10.
• Fondaparinux is contraindicated for primary PCI because of catheter‑thrombosis risk (Class III, Level A) 10.

Fibrinolytic Therapy – When Primary PCI Cannot Be Performed Within 120 min

• If primary PCI cannot be achieved within 120 minutes of STEMI diagnosis, give fibrinolysis within 12 hours of symptom onset in patients without contraindications (Class I, Level A) 10.
• Initiate fibrinolysis as early as possible, preferably in the pre‑hospital setting; each minute of delay increases mortality (Class I, Level A) 10.
• Use a fibrin‑specific agent (tenecteplase, alteplase, or reteplase) (Class I, Level A) 10.
• Administer aspirin (oral or IV) together with the fibrinolytic (Class I, Level A) 10.
• Add clopidogrel to aspirin for dual antiplatelet therapy (Class I, Level A) 10.
• Prefer enoxaparin (IV bolus followed by sub‑cutaneous dosing) for anticoagulation; a weight‑adjusted UFH bolus plus infusion is an acceptable alternative (Class I, Level A) 10.

Post‑Fibrinolysis Management

• Transfer all fibrinolysed patients immediately to a PCI‑capable centre (Class I, Level A) 10.
• Perform emergency angiography and PCI without delay if the patient develops heart failure, cardiogenic shock, haemodynamic or electrical instability (Class I, Level A) 10.
• Initiate rescue PCI promptly if fibrinolysis fails (≤50 % ST‑segment resolution at 60–90 min) or if instability occurs (Class I, Level A) 10.
• In stable patients after successful fibrinolysis, schedule angiography/PCI of the infarct‑related artery between 2 and 24 hours post‑therapy (Class I, Level A) 10.

In‑Hospital Pharmacotherapy

Antiplatelet and Anticoagulation Maintenance

• Continue dual antiplatelet therapy (aspirin 75–100 mg daily + ticagrelor or prasugrel) for 12 months unless bleeding risk is excessive (Class I, Level A) 11.
• Add a proton‑pump inhibitor in patients at high risk of gastrointestinal bleeding (Class IIa, Level B) 11.

Cardioprotective Medications

• Initiate high‑intensity statin therapy early and continue long‑term; target LDL‑C < 1.8 mmol/L (≈70 mg/dL) or ≥50 % reduction if baseline 1.8–3.5 mmol/L (Class I, Level A) 11.
• Start an ACE inhibitor within the first 24 hours in patients with heart failure, LVEF < 40 %, diabetes, or anterior infarction; an ARB (e.g., valsartan) is an alternative for ACE‑intolerant patients (Class I, Level A) 11.
• Begin oral beta‑blocker therapy in patients with heart failure and/or LVEF < 40 % unless contraindicated (Class I, Level A) 11.
• Add a mineralocorticoid‑receptor antagonist in patients with LVEF < 40 % and heart failure or diabetes who are already on ACE‑inhibitor and beta‑blocker, provided renal function and potassium are acceptable (Class IIa, Level A) 11.

Special Clinical Situations

Cardiac Arrest with STEMI

• Pursue primary PCI in patients resuscitated from cardiac arrest who show STEMI on ECG (Class I, Level A) 10.
• Initiate targeted temperature management early in unresponsive, post‑ROSC patients (Class I, Level A) 10.
• Do not use pre‑hospital cooling with large volumes of cold IV fluid after ROSC; this is contraindicated (Class III, Level A) 10.

Late Presentation

• Do not perform routine PCI of an occluded infarct‑related artery beyond 48 hours after STEMI onset in asymptomatic patients, as it does not improve outcomes (Class III, Level A) 10.

Critical Pitfalls to Avoid

• Avoid intravenous beta‑blockers in patients with hypotension, acute heart failure, high‑grade AV block, or severe bradycardia (Class III, Level A) 11.
• Do not use fondaparinux as anticoagulation for primary PCI because of catheter‑thrombosis risk (Class III, Level A) 10.

Post‑Acute Assessment and Secondary Prevention

• Perform routine echocardiography during the hospital stay to evaluate ventricular function, detect early mechanical complications, and exclude left‑ventricular thrombus (Class I, Level A) 10.
• Identify smokers and provide repeated cessation counselling with pharmacotherapy (varenicline, bupropion, or nicotine replacement) and behavioural support (Class I, Level B) 11.
• Enrol all patients in a structured cardiac rehabilitation programme (Class I, Level A) 11.

Guideline Framework

• The 2017 ESC STEMI guidelines constitute the most comprehensive, evidence‑based framework for acute MI management, emphasizing rapid reperfusion and immediate, guideline‑directed adjunctive therapy (Class I, Level A) 10.

Guideline‑Directed Management of Acute Myocardial Infarction

Immediate Diagnostic and Stabilization (First 10 minutes)

• The European Society of Cardiology (ESC) recommends obtaining a 12‑lead ECG within 10 minutes of arrival and initiating continuous cardiac monitoring with defibrillator capability. 12
• The ESC advises giving a loading dose of aspirin 75–100 mg orally or intravenously immediately on suspicion of acute MI, unless there is active bleeding or a severe allergy. 13

Reperfusion Strategy

Primary Percutaneous Coronary Intervention (PCI) – Preferred When Feasible

• The ESC states that primary PCI is the default reperfusion method when it can be performed without delay (door‑to‑balloon ≤ 90–120 min). 12
• Patients presenting within 12 hours of symptom onset with persistent ST‑segment elevation should be transferred directly to the catheterization laboratory, bypassing the emergency department and ICU to minimise door‑to‑balloon time. 13
• PCI‑capable centres must provide 24/7 service and be able to activate the catheter laboratory immediately for eligible patients. 12

Antithrombotic Therapy for Primary PCI

• A potent P2Y12 inhibitor (prasugrel or ticagrelor) should be administered before or at the time of PCI; clopidogrel is reserved for cases where the preferred agents are unavailable or contraindicated. 13
• Dual antiplatelet therapy (aspirin + P2Y12 inhibitor) is recommended for 12 months after PCI unless bleeding risk is prohibitive. 12
• Unfractionated heparin or low‑molecular‑weight heparin (enoxaparin) should be used for intraprocedural anticoagulation. 13
• Fondaparinux is contraindicated for primary PCI because of an increased risk of catheter‑related thrombosis. 12

Fibrinolytic Therapy – When Primary PCI Cannot Be Delivered Timely

• If primary PCI cannot be performed within 120 minutes of STEMI diagnosis, the ESC recommends administering fibrinolytic therapy within 12 hours of symptom onset in patients without contraindications. 13
• Fibrinolysis should be initiated as early as possible, preferably in the pre‑hospital setting, because each minute of delay raises mortality. 12
• A fibrin‑specific agent (tenecteplase, alteplase, or reteplase) is the preferred choice. 13
• Aspirin (oral or IV) should be given together with the fibrinolytic, and clopidogrel added for dual antiplatelet therapy. 12
• Enoxaparin (IV bolus followed by subcutaneous dosing) is the preferred anticoagulant; weight‑adjusted unfractionated heparin bolus plus infusion is an acceptable alternative. 13

Post‑Fibrinolysis Management

• All patients who receive fibrinolysis must be transferred immediately to a PCI‑capable centre. 12
• Emergency angiography and PCI without delay are required for patients who develop heart failure, cardiogenic shock, hemodynamic or electrical instability. 13
• Rescue PCI should be performed promptly if fibrinolysis fails (≤ 50 % ST‑segment resolution at 60–90 min) or if the patient becomes unstable at any time. 12
• In stable patients after successful fibrinolysis, angiography and PCI of the infarct‑related artery should be scheduled between 2 and 24 hours post‑therapy. 13

In‑Hospital Pharmacotherapy

Cardioprotective Medications

• An ACE inhibitor should be started within the first 24 hours in patients with heart failure, left‑ventricular ejection fraction < 40 %, diabetes, or anterior infarction. 12
• Oral beta‑blockers are indicated for patients with heart failure and/or left‑ventricular ejection fraction < 40 % unless contraindicated. Intravenous beta‑blockers are avoided in hypotension, acute heart failure, high‑grade AV block, or severe bradycardia. 13

Special Clinical Scenarios

Cardiac Arrest with STEMI

• After successful resuscitation from cardiac arrest, patients with STEMI should undergo primary PCI. 13
• Targeted temperature management should be initiated early in resuscitated patients who remain unresponsive. 13
• Pre‑hospital cooling with large volumes of cold IV fluid should be avoided immediately after return of spontaneous circulation. 13

Late Presentation (> 48 hours)

• Routine PCI of an occluded infarct‑related artery beyond 48 hours in asymptomatic patients does not improve outcomes and should not be performed. 12

Early In‑Hospital Assessment

• Routine transthoracic echocardiography during the hospital stay is recommended to evaluate ventricular function, detect early mechanical complications, and exclude left‑ventricular thrombus. 13

Secondary Prevention Initiated During Hospitalization

• All smokers should receive repeated cessation counseling and be offered pharmacotherapy (e.g., varenicline, bupropion, nicotine replacement) plus behavioral support. 12
• Every patient should be enrolled in a structured cardiac rehabilitation program before discharge. 13

Systems of Care and Pre‑Hospital Management

• Regional STEMI networks should be organised to deliver reperfusion therapy expeditiously, prioritising primary PCI whenever feasible. 12
• Primary PCI‑capable centres must maintain 24/7 availability and be able to perform primary PCI without delay. 13

Acute Myocardial Infarction – ESC Guideline‑Directed Management

Immediate Diagnostic Evaluation (First 10 minutes)

• The ESC guidelines recommend obtaining a 12‑lead ECG within 10 minutes of first medical contact to identify ST‑segment elevation, new left‑bundle‑branch block, or posterior MI patterns. 14
• The ESC guidelines advise initiating continuous cardiac monitoring with defibrillator capability at the bedside to detect life‑threatening arrhythmias. 15
• The ESC guidelines state that aspirin 75–100 mg should be given orally or intravenously immediately unless active bleeding or severe allergy is present. 16
• The ESC guidelines recommend avoiding routine supplemental oxygen unless peripheral oxygen saturation is < 90 %; routine oxygen does not improve outcomes and may cause harm. 17

Reperfusion Strategy Selection

Primary PCI (Preferred Method)

• The ESC guidelines designate primary percutaneous coronary intervention (PCI) as the default reperfusion method and require performance without delay when feasible. 14
• The ESC guidelines instruct that STEMI patients be transferred directly to the catheterisation laboratory, bypassing the emergency department and intensive‑care unit. 15
• The ESC guidelines require immediate activation of the catheterisation laboratory upon STEMI diagnosis; PCI‑capable centres must provide 24/7 service. 17
• The ESC guidelines indicate reperfusion therapy for all patients with ischemic symptoms < 12 hours and persistent ST‑segment elevation. 16

Antithrombotic Therapy for Primary PCI

• The ESC guidelines advise administering a potent P2Y12 inhibitor (prasugrel or ticagrelor preferred; clopidogrel only if the former are unavailable or contraindicated) before or at the time of PCI. 14
• The ESC guidelines recommend continuing dual antiplatelet therapy (aspirin 75–100 mg daily + prasugrel or ticagrelor) for 12 months unless bleeding risk is excessive. 15
• The ESC guidelines endorse unfractionated heparin or enoxaparin for intraprocedural anticoagulation during primary PCI. 17
• The ESC guidelines caution against using fondaparinux for primary PCI because of an increased risk of catheter‑related thrombosis. 16
• The ESC guidelines endorse radial arterial access as the standard approach during primary PCI to minimise bleeding complications. 17

Fibrinolytic Therapy (When Primary PCI > 120 min)

• The ESC guidelines state that if primary PCI cannot be performed within 120 minutes of STEMI diagnosis, fibrinolytic therapy should be administered within 12 hours of symptom onset in patients without contraindications. 14
• The ESC guidelines stress that fibrinolysis be initiated as early as possible, preferably in the pre‑hospital setting; each minute of delay increases mortality. 16
• The ESC guidelines specify the use of fibrin‑specific agents (tenecteplase, alteplase, or reteplase). 14
• The ESC guidelines require co‑administration of aspirin (oral or IV) with the fibrinolytic agent. 16
• The ESC guidelines add clopidogrel to aspirin for dual antiplatelet therapy during fibrinolysis. 14
• The ESC guidelines recommend enoxaparin (IV bolus followed by sub‑cutaneous dosing) as the preferred anticoagulant for fibrinolysis; a weight‑adjusted unfractionated heparin bolus plus infusion is an acceptable alternative. 16
• The ESC guidelines advise continuing anticoagulation until revascularisation or for the duration of the hospital stay, up to 8 days. 14

Post‑Fibrinolysis Management

• The ESC guidelines mandate immediate transfer of all fibrinolyzed patients to a PCI‑capable centre after fibrinolytic administration. 16
• The ESC guidelines require emergency angiography and PCI without delay if the patient develops heart failure, cardiogenic shock, haemodynamic instability, or electrical instability. 14
• The ESC guidelines call for rescue PCI immediately if fibrinolysis fails (≤ 50 % ST‑segment resolution at 60–90 minutes) or if instability occurs at any time. 16
• The ESC guidelines recommend that, in stable patients after successful fibrinolysis, angiography and PCI of the infarct‑related artery be scheduled between 2 and 24 hours post‑therapy. 14

Management of Non‑Culprit Lesions

• The ESC guidelines advise treating severe stenosis in non‑infarct‑related arteries (identified by angiography or FFR) before hospital discharge, either during the index PCI or in a staged procedure. 17
• The ESC guidelines state that, in cardiogenic shock, PCI of non‑infarct‑related arteries should be performed during the index procedure. 17

Special Clinical Scenarios

Cardiac Arrest with STEMI

• The ESC guidelines recommend pursuing primary PCI in patients who are successfully resuscitated from cardiac arrest and show STEMI on the post‑resuscitation ECG. 15
• The ESC guidelines advise early initiation of targeted temperature management in resuscitated patients who remain unresponsive. 17
• The ESC guidelines caution against pre‑hospital cooling with large volumes of cold intravenous fluid immediately after return of spontaneous circulation. 14

Late Presentation (> 48 hours)

• The ESC guidelines advise against routine PCI of an occluded infarct‑related artery beyond 48 hours after STEMI onset in asymptomatic patients, as this does not improve outcomes. 16

MINOCA (Myocardial Infarction with Non‑Obstructive Coronary Arteries)

• The ESC guidelines recommend additional diagnostic testing (cardiac MRI, intravascular imaging, provocative testing) in patients without significant coronary stenosis on urgent angiography to identify the underlying aetiology and guide therapy. 15

In‑Hospital Pharmacotherapy

Cardioprotective Medications

• The ESC guidelines endorse initiating high‑intensity statin therapy as early as possible and continuing long‑term; target LDL‑C < 1.8 mmol/L (≈ 70 mg/dL) or ≥ 50 % reduction if baseline is higher. 16
• The ESC guidelines advise starting an ACE inhibitor within the first 24 hours in patients with heart failure, left‑ventricular ejection fraction < 40 %, diabetes, or anterior MI; an ARB is recommended for ACE‑intolerant patients. 16
• The ESC guidelines recommend initiating oral beta‑blocker therapy in patients with heart failure and/or left‑ventricular ejection fraction < 40 % unless contraindicated. 16
• The ESC guidelines prohibit intravenous beta‑blockers in patients with hypotension, acute heart failure, high‑grade AV block, or severe bradycardia. 16

Critical Pitfalls

• The ESC guidelines stress cautious use of intravenous morphine, noting observational data linking it to higher rates of death, myocardial infarction, and the composite of death/MI compared with no morphine. (strength not specified)

Early In‑Hospital Assessment

• The ESC guidelines recommend routine transthoracic echocardiography during the hospital stay to assess left‑ and right‑ventricular function, detect early mechanical complications (ventricular septal defect, papillary‑muscle rupture, free‑wall rupture), and exclude left‑ventricular thrombus. 14
• The ESC guidelines require monitoring patients for at least 24 hours after reperfusion therapy in a coronary‑care or intensive‑care unit setting. 15

Secondary Prevention Initiated During Hospitalisation

• The ESC guidelines call for systematic identification of all smokers and provision of repeated cessation counselling together with pharmacotherapy options (varenicline, bupropion, or nicotine‑replacement therapy). 14
• The ESC guidelines mandate enrolment of every patient in a structured cardiac‑rehabilitation programme before discharge. 16

Special Patient Populations

Renal Dysfunction

• The ESC guidelines emphasise dose adjustment of antithrombotic and antiplatelet agents in patients with advanced renal dysfunction (eGFR < 30 mL/min/1.73 m²). 15

Elderly Patients and Those on Oral Anticoagulants

• The ESC guidelines advise careful balancing of ischaemic and bleeding risks when adjusting antithrombotic therapy in elderly patients and those receiving oral anticoagulants. 17

Diabetic Patients

• The ESC guidelines recommend intensified glycaemic control and aggressive secondary‑prevention measures in diabetic patients. 15

Systems of Care and Pre‑Hospital Management

• The ESC guidelines advocate organising regional STEMI networks with written protocols that coordinate emergency medical services and hospitals to deliver reperfusion therapy expeditiously, aiming to make primary PCI available to as many patients as possible. 14
• The ESC guidelines require EMS to alert the PCI centre immediately after STEMI diagnosis and selection of the reperfusion strategy. 17
• The ESC guidelines stipulate that primary PCI‑capable centres must maintain 24/7 availability and be able to perform primary PCI without delay. 15

Quality Indicators

• The ESC guidelines propose using well‑defined, validated quality indicators to measure and improve STEMI care, including door‑to‑ECG time, door‑to‑balloon time, door‑to‑needle time, and rates of guideline‑directed medical therapy at discharge. 15
• The ESC guidelines recommend regular audit of practice to reduce the gap between optimal guideline‑based treatment and actual care of STEMI patients. 17

Guideline‑Directed Management and Outcomes for STEMI Patients Unable to Receive Reperfusion

Pharmacologic Therapy When Reperfusion Is Not Feasible

• Anticoagulation with enoxaparin (IV bolus followed by subcutaneous dosing) or weight‑adjusted unfractionated heparin is recommended; fondaparinux reduces death or reinfarction without increasing bleeding in STEMI patients who do not undergo reperfusion. (American College of Cardiology) 18
• Aspirin, clopidogrel, and high‑intensity statin therapy should be initiated promptly and not delayed or omitted in patients who cannot receive reperfusion, because these agents confer a mortality benefit even without reperfusion. (American College of Cardiology) 18
• ACE‑inhibitor and beta‑blocker therapy should be incorporated as part of aggressive guideline‑directed medical therapy for non‑reperfused STEMI, targeting patients with heart failure, reduced LVEF, diabetes, or anterior infarction. (American College of Cardiology) 18

Documented Reasons for Not Providing Reperfusion

• The most common documented reasons for withholding reperfusion are coronary anatomy unsuitable for PCI (≈33% of cases), absence of an ischemic indication on reassessment (≈54% of contraindications), bleeding risk (≈17%), and patient refusal or comorbidities (≈25%). (American College of Cardiology) 18

Clinical Pitfalls to Avoid

• Advanced age, female sex, and the presence of comorbidities should not be used alone to withhold reperfusion; these factors are associated with undertreatment but are not absolute contraindications. (American College of Cardiology) 18
• Do not assume that spontaneous reperfusion or true contraindications account for most non‑reperfusion cases; the majority result from delayed presentation or system‑level failures in care delivery. (American College of Cardiology) 18

Late Reperfusion Considerations

• In patients presenting 12–48 hours after symptom onset who remain symptomatic with ongoing ischemia or hemodynamic compromise, late PCI may still provide outcome benefits and should be considered. (American College of Cardiology) 18

Overall Survival Strategy for Non‑Reperfused STEMI

• For the minority of patients truly unable to receive reperfusion, aggressive guideline‑directed medical therapy—including dual antiplatelet agents, anticoagulation, high‑intensity statins, ACE inhibitors, and beta‑blockers—is essential to optimize survival. (American College of Cardiology) 18

Acute Management of ST‑Elevation Myocardial Infarction (STEMI) – Evidence‑Based Recommendations

Immediate Diagnostic Actions

• Obtain a 12‑lead electrocardiogram within the first 10 minutes of patient arrival to confirm ST‑segment elevation or a new left‑bundle‑branch block. 19

Primary Reperfusion Strategy (PCI)

• Primary percutaneous coronary intervention (PCI) is the default reperfusion method when the first‑medical‑contact‑to‑device time can be ≤ 90 minutes for patients presenting directly to a PCI‑capable centre, or ≤ 120 minutes for patients transferred from another facility. 19
• Transfer the patient directly to the cardiac catheterisation laboratory, bypassing the emergency department and intensive‑care unit, to minimise door‑to‑balloon time. 19

Fibrinolytic Reperfusion When PCI Is Not Feasible

• If primary PCI cannot be performed within 120 minutes of STEMI diagnosis, administer fibrinolytic therapy within 12 hours of symptom onset in patients without contraindications. 19
• After fibrinolysis, transfer the patient immediately to a PCI‑capable centre for further management. 19
• In patients who are haemodynamically stable after successful fibrinolysis, schedule angiography and PCI of the infarct‑related artery between 2 and 24 hours post‑therapy (pharmacoinvasive strategy). 19

Organisation of Care – Regional STEMI Networks

• Optimal STEMI care is delivered through organised regional networks in which a PCI‑capable “hub” hospital receives referrals from surrounding “spoke” hospitals and direct field transfers by emergency medical services. 19

Decision Algorithms for Non‑PCI Centres

• When the estimated first‑medical‑contact‑to‑PCI time is < 120 minutes, the patient should be transferred for primary PCI. 19
• When the estimated first‑medical‑contact‑to‑PCI time will exceed 120 minutes, fibrinolysis should be given with a target first‑medical‑contact‑to‑needle time < 30 minutes, followed by rapid transfer for angiography within 2 to 24 hours. 19

Management of STEMI in Patients Receiving Rivaroxaban

Immediate Reperfusion

• The European Society of Cardiology (ESC) states that reperfusion therapy must not be delayed or withheld because the patient is on rivaroxaban; primary PCI or fibrinolysis should be initiated immediately according to standard STEMI protocols. 20
• The ESC recommends obtaining a 12‑lead ECG within 10 minutes, administering aspirin 75–100 mg (oral or IV) promptly, and activating the cardiac catheterisation laboratory to achieve primary PCI within 90–120 minutes of first medical contact. 20

Periprocedural Anticoagulation During Primary PCI

• The ESC and the American College of Cardiology (ACC) advise using unfractionated heparin (UFH) or enoxaparin for intraprocedural anticoagulation; fondaparinux should be avoided. 20, 21
• The ACC recommends that patients on rivaroxaban receive additional UFH boluses, with activated clotting time (ACT) monitoring and dose adjustment, especially when glycoprotein IIb/IIIa inhibitors are employed. 22, 21
• The ACC notes that rivaroxaban contributes to baseline anticoagulation, so ACT should be closely monitored and UFH dosing tailored accordingly. 21
• The ESC and ACC consider fondaparinux absolutely contraindicated for primary PCI because of a high risk of catheter thrombosis, irrespective of prior rivaroxaban use. 20, 21

Antiplatelet Therapy

• The ESC recommends administering a potent P2Y12 inhibitor—ticagrelor preferred; prasugrel or clopidogrel may be used if ticagrelor is unavailable or contraindicated—before or at the time of PCI. 20
• In patients aged ≥ 75 years, the ACC and ESC prefer ticagrelor over prasugrel because prasugrel is contraindicated in those with prior stroke/TIA and carries a higher bleeding risk in the elderly. 22, 20
• The ESC advises continuation of dual antiplatelet therapy (aspirin 75–100 mg daily + ticagrelor) for 12 months after PCI. 20

Post‑PCI Antithrombotic Strategy

• The American Heart Association/American College of Cardiology (AHA/ACC) indicates that, when a compelling indication for anticoagulation exists (e.g., atrial fibrillation, mechanical valve, VTE), triple therapy (aspirin + P2Y12 inhibitor + rivaroxaban) should be employed after successful PCI. 23
• For atrial fibrillation, the AHA/ACC recommends continuing rivaroxaban at the dose appropriate for renal function (15 mg daily if creatinine clearance 30–50 mL/min; 20 mg daily if > 50 mL/min) together with dual antiplatelet therapy initially. 23
• Based on the PIONEER AF‑PCI paradigm, the AHA/ACC suggests dropping aspirin after about 1 month and maintaining dual therapy with rivaroxaban plus a P2Y12 inhibitor to lower bleeding risk. 23
• If rivaroxaban was prescribed for a time‑limited indication (e.g., recent DVT/PE), the AHA/ACC advises reassessing the need for anticoagulation after the acute STEMI phase and discontinuing it if no longer required. 23

Bleeding‑Risk Mitigation

• The ESC and AHA/ACC recommend radial arterial access for PCI, routine proton‑pump‑inhibitor use, and early de‑escalation from triple to dual therapy to mitigate the markedly increased bleeding risk in elderly patients on triple therapy. 20, 23

Fibrinolysis When Primary PCI Is Not Feasible

• The ESC states that if primary PCI cannot be performed within 120 minutes of STEMI diagnosis, fibrinolytic therapy should be administered within 12 hours of symptom onset, provided no contraindications exist. 20
• The ESC and ACC note that active rivaroxaban is not an absolute contraindication to fibrinolysis but does raise bleeding risk; clinicians must weigh the risk‑benefit ratio. 20, 21
• When the last rivaroxaban dose was taken within 12 hours, the ESC advises that the bleeding risk (especially intracranial hemorrhage) is substantially higher, and emergency transfer for primary PCI should be prioritized even if this exceeds the 120‑minute window. 20

Anticoagulation After Fibrinolysis

• The ESC and ACC recommend using enoxaparin (intravenous bolus followed by subcutaneous dosing) for post‑fibrinolysis anticoagulation and advise against adding rivaroxaban during the acute phase. 20, 21
• The ESC advises immediate transfer to a PCI‑capable centre after fibrinolysis for coronary angiography within 2–24 hours. 20
• The AHA/ACC suggests resuming rivaroxaban only after successful angiography/PCI and after reassessing bleeding risk, typically 24–48 hours later if a continued anticoagulation indication persists. 23

Reversal of Rivaroxaban

• The AHA/ACC reports that andexanet alfa is available to reverse rivaroxaban’s anti‑factor Xa activity in life‑threatening bleeding; it reduces median anti‑Xa activity by ~89 % within 2 hours, though thrombotic events occurred in 18 % of patients during 30‑day follow‑up (ANNEXA‑4). 23

Critical Pitfalls to Avoid

• The ESC cautions against postponing reperfusion to reverse rivaroxaban or to obtain coagulation studies; STEMI management must take absolute priority. 20
• The ESC and ACC reiterate that fondaparinux must not be used for primary PCI, even in patients already receiving rivaroxaban. 20, 21
• The ACC emphasizes that rivaroxaban alone does not provide sufficient periprocedural anticoagulation; UFH or enoxaparin must always be added. 22, 21
• The AHA/ACC advises limiting triple therapy to ≤ 1 month unless the ischemic benefit clearly outweighs bleeding risk, with early de‑escalation planned. 23
• The ACC warns against using prasugrel in elderly patients with any history of stroke/TIA. 22

Adjunctive Therapies

• The ESC recommends initiating high‑intensity statin therapy, an ACE inhibitor (if heart failure, LVEF < 40 %, diabetes, or anterior MI), and an oral beta‑blocker (if heart failure or LVEF < 40 %) within 24 hours of presentation, unless contraindicated. 20
• The ESC advises avoiding intravenous beta‑blockers in the presence of hypotension, acute heart failure, high‑grade AV block, or severe bradycardia. 20
• The ESC suggests routine echocardiography during hospitalization to evaluate left‑ventricular function, detect mechanical complications, and rule out left‑ventricular thrombus. 20

Standardized Admission Orders for Acute Myocardial Infarction

Immediate Diagnostic and Therapeutic Actions (First 10 minutes)

• In patients presenting with suspected acute myocardial infarction, obtain a 12‑lead electrocardiogram within 10 minutes to identify ST‑segment elevation, new left‑bundle‑branch block, or posterior infarction patterns. 24
• Administer a single dose of aspirin 75–100 mg orally or intravenously immediately on arrival, provided there is no active bleeding or severe allergy. 24
• Initiate bedside continuous cardiac monitoring with defibrillator capability to detect life‑threatening arrhythmias. 24
• Reserve supplemental oxygen for patients whose peripheral oxygen saturation is < 90 %; routine oxygen therapy does not improve outcomes and may cause harm. 24

Reperfusion Strategy

Primary Percutaneous Coronary Intervention (PCI)

• Transfer patients with ST‑elevation myocardial infarction directly to the cardiac catheterization laboratory, bypassing the emergency department and intensive‑care unit, to minimize door‑to‑balloon time. 24
• Activate the catheterization laboratory immediately after STEMI diagnosis; PCI‑capable centers should provide 24/7 service. 24
• Give a potent P2Y12 inhibitor before or at the time of PCI—ticagrelor 180 mg loading dose is preferred; prasugrel 60 mg is an alternative but contraindicated in patients ≥ 75 years with prior stroke/TIA; clopidogrel 600 mg may be used only if the former agents are unavailable. 24
• Use unfractionated heparin (70–100 U/kg bolus, target ACT 250–350 s) or enoxaparin (0.5 mg/kg IV bolus) for intraprocedural anticoagulation. 24
• Avoid fondaparinux for primary PCI because of a high risk of catheter‑thrombosis. 24

Fibrinolytic Therapy (When Primary PCI > 120 min)

• If primary PCI cannot be performed within 120 minutes of STEMI diagnosis, administer fibrinolytic therapy within 12 hours of symptom onset, provided no contraindications exist. 24
• Choose a fibrin‑specific agent (tenecteplase, alteplase, or reteplase) for thrombolysis. 24
• Add a clopidogrel loading dose (300 mg; 75 mg if age > 75 years) to aspirin for dual antiplatelet therapy. 24
• Provide anticoagulation with enoxaparin (30 mg IV bolus then 1 mg/kg subcutaneously every 12 h) or weight‑adjusted unfractionated heparin (60 U/kg bolus, then infusion targeting aPTT 50–70 s). 24
• Arrange immediate transfer to a PCI‑capable center after fibrinolysis. 24
• Schedule coronary angiography and PCI of the infarct‑related artery between 2 and 24 hours after successful fibrinolysis in stable patients; perform emergency angiography and PCI without delay if heart failure, cardiogenic shock, hemodynamic or electrical instability develops. 24
• Initiate rescue PCI promptly when fibrinolysis fails (≤ 50 % ST‑segment resolution at 60–90 min). 24

Unit Assignment and Monitoring

• Admit patients with ongoing angina, hemodynamic instability, uncontrolled arrhythmias, large infarcts with heart failure, or cardiogenic shock to a cardiac intensive‑care unit (CICU). 24
• Admit stable patients without recurrent ischemia, significant arrhythmias, pulmonary edema, or hemodynamic compromise to an intermediate‑care or telemetry unit. 24
• Ensure continuous electrocardiographic rhythm monitoring, frequent vital‑sign assessment, and immediate defibrillation capability with appropriate nurse‑to‑patient ratios. 24

Adjunctive Pharmacotherapy (First 24 hours)

Cardioprotective Medications

• Start high‑intensity statin therapy immediately (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) aiming for LDL‑C < 1.8 mmol/L (≈70 mg/dL) or ≥ 50 % reduction. 24
• Initiate an ACE inhibitor within the first 24 hours in patients with heart failure, left‑ventricular ejection fraction < 40 %, diabetes, or anterior infarction; use an ARB (e.g., valsartan 40–80 mg twice daily) if ACE inhibition is not tolerated. 24
• Begin oral beta‑blocker therapy in patients with heart failure and/or LVEF < 40 % unless contraindicated (e.g., metoprolol tartrate 25–50 mg twice daily or carvedilol 3.125–6.25 mg twice daily, titrated upward). 24
• Avoid intravenous beta‑blockers in the presence of hypotension, acute heart failure, high‑grade AV block, or severe bradycardia. 24

Antiplatelet and Anticoagulation Maintenance

• Continue dual antiplatelet therapy (aspirin 75–100 mg daily + ticagrelor 90 mg twice daily or prasugrel 10 mg daily) for 12 months unless bleeding risk is excessive. 24

Anemia Management

• In patients with acute or chronic anemia, consider red‑blood‑cell transfusion to achieve a hemoglobin level ≥ 10 g/dL to reduce cardiovascular events, recognizing that observational data associate transfusion with worse outcomes and that randomized trials in other populations favor a restrictive strategy (target hemoglobin ≈ 8 g/dL). 24

Early In‑Hospital Cardiac Assessment

• Perform routine transthoracic echocardiography during hospitalization to evaluate left‑ and right‑ventricular function, detect early mechanical complications (ventricular septal defect, papillary‑muscle rupture, free‑wall rupture), and rule out left‑ventricular thrombus. 24

Critical Pitfalls to Avoid

• Do not delay reperfusion therapy for routine echocardiography or other non‑essential testing in clear STEMI cases. 24
• Do not perform routine PCI of an occluded infarct‑related artery beyond 48 hours after STEMI onset in asymptomatic patients. 24
• Do not use fondaparinux as anticoagulation for primary PCI. 24
• Do not prescribe glucocorticoids or non‑steroidal anti‑inflammatory drugs (other than aspirin) because of potential increased risk of recurrent MI, impaired myocardial healing, and risk of rupture. 24

Acute Myocardial Infarction – Immediate Treatment Guidelines

Initial Diagnosis and Early Management

• Obtain a 12‑lead electrocardiogram within 10 minutes of patient arrival to identify ST‑segment elevation or new left‑bundle‑branch block. 25
• Administer aspirin 75–100 mg orally or intravenously immediately on arrival, provided there is no active bleeding or severe allergy. 25

Reperfusion Strategy Selection

Primary Percutaneous Coronary Intervention (PCI)

• Primary PCI is the preferred reperfusion method when the first‑medical‑contact‑to‑device time can be achieved ≤90 minutes for patients presenting directly or ≤120 minutes for transferred patients. 25
• Transfer the patient directly to the cardiac catheterisation laboratory, bypassing the emergency department and intensive‑care unit, to minimise door‑to‑balloon time. 25

Fibrinolytic Therapy (when PCI cannot be performed within 120 minutes)

• If primary PCI cannot be performed within 120 minutes of STEMI diagnosis, give a fibrinolytic agent within 12 hours of symptom onset in patients without contraindications. 25
• Use a fibrin‑specific agent (tenecteplase, alteplase, or reteplase). 26
• Add a clopidogrel loading dose (300 mg; 75 mg if age > 75 years) to aspirin for dual antiplatelet therapy after fibrinolysis. 26
• Anticoagulation during fibrinolysis can be provided with enoxaparin (30 mg IV bolus then 1 mg/kg subcutaneously every 12 h) or weight‑adjusted unfractionated heparin (60 U/kg bolus followed by infusion targeting aPTT 50–70 seconds). 26

Antithrombotic Therapy for Primary PCI

• P2Y12 inhibition: give a ticagrelor 180 mg loading dose (preferred); prasugrel 60 mg is an alternative but contraindicated in patients ≥ 75 years or with prior stroke/TIA; clopidogrel 600 mg only if the former agents are unavailable. 25
• Continue dual antiplatelet therapy (aspirin 75–100 mg daily + ticagrelor 90 mg twice daily or prasugrel 10 mg daily) for 12 months unless bleeding risk is excessive. 25
• Intraprocedural anticoagulation: unfractionated heparin 70–100 U/kg bolus (target ACT 250–350 seconds) or enoxaparin 0.5 mg/kg IV bolus. 26
• Radial arterial access is the standard approach to reduce bleeding complications. 25
• Fondaparinux must not be used for primary PCI because of a high risk of catheter‑thrombosis. 26

Post‑Fibrinolysis (Pharmacoinvasive) Management

• Transfer all patients who received fibrinolysis immediately to a PCI‑capable centre.
• Perform emergency angiography and PCI without delay if the patient develops heart failure, cardiogenic shock, haemodynamic or electrical instability. 26
• Initiate rescue PCI when fibrinolysis fails (≤50 % ST‑segment resolution at 60–90 minutes). 26
• In stable patients after successful fibrinolysis, schedule angiography and PCI of the infarct‑related artery between 2 and 24 hours post‑therapy. 26

Complete Revascularisation

• A complete revascularisation strategy is recommended for STEMI patients; PCI of significant non‑culprit lesions may be performed in a single procedure or staged, with a preference for a single‑procedure multivessel PCI. 25
• In cardiogenic shock, perform emergency revascularisation of the culprit vessel only; routine PCI of non‑infarct‑related arteries at the time of culprit PCI is not advised. 25

Adjunctive Pharmacotherapy (First 24 Hours)

Cardioprotective Medications

• Initiate high‑intensity statin therapy immediately (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) aiming for LDL‑C < 1.8 mmol/L (≈70 mg/dL) or ≥50 % reduction. 26
• Start an ACE inhibitor within the first 24 hours in patients with heart failure, left‑ventricular ejection fraction < 40 %, diabetes, or anterior MI; use an ARB if ACE inhibition is not tolerated. 26
• Begin an oral beta‑blocker in patients with heart failure and/or LVEF < 40 % unless contraindicated (e.g., hypotension, acute heart failure, high‑grade AV block, severe bradycardia). Intravenous beta‑blockers should be avoided in these situations. 26

Bleeding‑Risk Mitigation

• Add a proton‑pump inhibitor in patients at high risk of gastrointestinal bleeding. 25
• In patients who have tolerated dual antiplatelet therapy with ticagrelor, transition to ticagrelor monotherapy ≥1 month after PCI to reduce bleeding risk. 25

Cardiogenic Shock Management

• Emergency revascularisation (PCI or coronary‑artery bypass grafting) is recommended in suitable patients with cardiogenic shock after STEMI, irrespective of the time elapsed since MI onset. 26
• Use of a microaxial flow pump (e.g., Impella) is reasonable in selected shock patients to reduce mortality, acknowledging higher rates of bleeding, limb ischemia, and renal failure. Careful vascular‑access management and weaning are essential. 25
• Intra‑aortic balloon pump counter‑pulsation may be useful for patients whose shock does not rapidly stabilise with pharmacologic therapy. 26

Anemia Management

• Red‑blood‑cell transfusion to maintain a hemoglobin of 10 g/dL may be reasonable in patients with acute coronary syndrome and acute or chronic anemia who are not actively bleeding. 25

Contra‑indicated Practices (to Avoid)

• Fondaparinux must not be used as anticoagulation for primary PCI. 26
• Aspirin should not be withheld before urgent coronary‑artery bypass grafting. 26
• Non‑steroidal anti‑inflammatory drugs (other than aspirin) and glucocorticoids should be avoided because they increase the risk of recurrent MI, impair myocardial healing, and raise the risk of ventricular rupture.

All statements are derived from cited guideline sources.

Acute Management of Inferior ST‑Elevation Myocardial Infarction – Evidence‑Based Recommendations

Immediate Assessment (First 10 minutes)

• Obtain a 12‑lead ECG within 10 minutes of arrival and confirm ST‑segment elevation ≥ 1 mm in two contiguous inferior leads (II, III, aVF); examine lead aVL for reciprocal ST‑depression to strengthen the diagnosis of acute coronary occlusion. 27
• Give aspirin 75–100 mg orally or intravenously immediately, unless active bleeding or severe allergy is present. 27, 28
• Initiate continuous cardiac monitoring with defibrillator capability because inferior STEMI frequently causes high‑grade AV block, sinus bradycardia, and hemodynamic collapse. 27
• Avoid routine supplemental oxygen unless peripheral SpO₂ < 90 %; routine oxygen does not improve outcomes and may cause harm. 27

Reperfusion Strategy

Primary Percutaneous Coronary Intervention (PCI) – Preferred

• Immediate primary PCI is the default reperfusion strategy when it can be performed within 90–120 minutes of first medical contact; otherwise fibrinolytic therapy should be given within 12 hours of symptom onset. 27, 28
• Transfer the patient directly to the cardiac catheterisation laboratory, bypassing the emergency department and intensive‑care unit, to achieve a door‑to‑balloon time ≤ 90 minutes for direct presenters or ≤ 120 minutes for transferred patients. 27, 28
• Activate the catheterisation laboratory immediately upon STEMI diagnosis; PCI‑capable centres must provide 24/7 service. 27, 28
• Administer a potent P2Y12 inhibitor before or at the time of PCI: ticagrelor 180 mg loading dose is preferred; prasugrel 60 mg is an alternative but is contraindicated in patients ≥ 75 years or with prior stroke/TIA; clopidogrel 600 mg may be used if the former agents are unavailable. 27, 28
• Use unfractionated heparin (70–100 U/kg bolus, target ACT 250–350 seconds) or enoxaparin (0.5 mg/kg IV bolus) for intraprocedural anticoagulation. 27, 28
• Fondaparinux is absolutely contraindicated for primary PCI because of a high risk of catheter‑thrombosis. 27, 28
• Radial arterial access is the standard approach to minimise bleeding complications. 27

Fibrinolytic Therapy – When PCI Cannot Be Performed Within 120 minutes

• Administer fibrinolytic therapy within 12 hours of symptom onset if primary PCI cannot be performed within 120 minutes and no contraindications exist. 27, 28
• Initiate fibrinolysis as early as possible, preferably in the pre‑hospital setting; each minute of delay increases mortality. 27, 28
• Use a fibrin‑specific agent (tenecteplase, alteplase, or reteplase). 27, 28
• Add clopidogrel 300 mg loading dose (75 mg if age > 75 years) to aspirin for dual antiplatelet therapy. 27, 28
• Prefer enoxaparin (30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 h) for anticoagulation; weight‑adjusted unfractionated heparin (60 U/kg bolus then infusion targeting aPTT 50–70 seconds) is an acceptable alternative. 27, 28
• Continue anticoagulation until revascularisation or for the duration of the hospital stay, up to 8 days. 27, 28

Post‑Fibrinolysis (Pharmacoinvasive) Management

• Transfer all fibrinolysed patients immediately to a PCI‑capable centre after fibrinolytic administration. 27, 28
• Perform emergency angiography and PCI without delay if the patient develops heart failure, cardiogenic shock, haemodynamic instability, or electrical instability. 27, 28
• Initiate rescue PCI immediately if fibrinolysis fails (≤ 50 % ST‑segment resolution at 60–90 minutes) or if instability occurs at any time. 27, 28
• In stable patients after successful fibrinolysis, schedule angiography and PCI of the infarct‑related artery between 2 and 24 hours post‑therapy. 27, 28

Conduction Disturbances and Bradycardia

• High‑grade AV block, sinus bradycardia, and hypotension occur frequently in inferior STEMI because the right coronary artery typically supplies the AV and sinus nodes. 27
• Avoid intravenous β‑blockers in the presence of hypotension, acute heart failure, high‑grade AV block, or severe bradycardia. 27, 28

Adjunctive Pharmacotherapy (First 24 hours)

Cardioprotective Medications

• Initiate high‑intensity statin therapy immediately (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) aiming for LDL‑C < 1.8 mmol/L (≈ 70 mg/dL) or ≥ 50 % reduction. 27, 28
• Start an ACE inhibitor within the first 24 hours in patients with heart failure, left‑ventricular ejection fraction < 40 %, diabetes, or anterior infarction; use an ARB (e.g., valsartan 40–80 mg twice daily) if ACE inhibition is not tolerated. 27, 28
• Begin oral β‑blocker therapy in patients with heart failure and/or LVEF < 40 % unless contraindicated (metoprolol tartrate 25–50 mg twice daily or carvedilol 3.125–6.25 mg twice daily, titrated upward). 27, 28

Antiplatelet Maintenance

• Continue dual antiplatelet therapy (aspirin 75–100 mg daily + ticagrelor 90 mg twice daily or prasugrel 10 mg daily) for 12 months unless bleeding risk is excessive. 27, 28
• Add a proton‑pump inhibitor in patients at high risk of gastrointestinal bleeding. 27, 28

Critical Pitfalls to Avoid

• Do not delay reperfusion therapy to obtain echocardiography or other non‑essential testing in clear STEMI cases; reperfusion has absolute priority. 27
• Do not perform routine PCI of an occluded infarct‑related artery beyond 48 hours after STEMI onset in asymptomatic patients. 27, 28
• Do not use fondaparinux as anticoagulation for primary PCI. 27, 28

In‑Hospital Assessment and Secondary Prevention

• Perform routine transthoracic echocardiography during hospitalisation to evaluate left‑ and right‑ventricular function, detect early mechanical complications (ventricular septal defect, papillary‑muscle rupture, free‑wall rupture), and rule out left‑ventricular thrombus. 27, 28
• Identify all smokers and provide repeated cessation counselling together with pharmacotherapy options (varenicline, bupropion, or nicotine‑replacement therapy). 27, 28
• Enrol every patient in a structured cardiac‑rehabilitation programme before discharge. 27, 28

Reperfusion and Early Management of ST‑Elevation Myocardial Infarction (STEMI)

Immediate Diagnostic Evaluation (first 10 min)

• Obtain a 12‑lead electrocardiogram within 10 minutes of first medical contact to detect ST‑segment elevation, new left‑bundle‑branch block, or posterior infarction patterns. ESC recommendation. 29
• Initiate continuous cardiac monitoring with immediate defibrillation capability to detect life‑threatening arrhythmias. ESC recommendation. 29
• Give aspirin 75–100 mg orally or intravenously immediately, unless active bleeding or severe allergy is present. ESC recommendation. [29][30]
• Reserve routine supplemental oxygen for patients with peripheral oxygen saturation < 90 %; routine oxygen does not improve outcomes and may cause harm. ESC recommendation. 29

Primary Percutaneous Coronary Intervention (PCI) – Preferred Reperfusion Strategy

• Primary PCI is the default reperfusion method when it can be performed without delay (contact‑to‑device time ≤ 90–120 min). ESC Class I, Level A. [29][31]
• Transfer the patient directly to the cardiac catheterisation laboratory, bypassing the emergency department and intensive‑care unit, to minimise door‑to‑balloon time. ESC Class I, Level A. [29][31]
• Centres capable of primary PCI must provide 24/7 service and be able to start PCI without delay. ESC recommendation. 29
• Administer a potent P2Y12 inhibitor before or at the time of PCI: ticagrelor 180 mg loading dose (preferred); prasugrel 60 mg is an alternative but contraindicated in patients ≥ 75 years or with prior stroke/TIA; clopidogrel 600 mg only if the other agents are unavailable. ESC Class I, Level A. [29][30]
• Use unfractionated heparin (70–100 U/kg bolus, target ACT 250–350 s) or enoxaparin (0.5 mg/kg IV bolus) for intraprocedural anticoagulation. ESC Class I, Level A. [29][31]
• Fondaparinux is absolutely contraindicated for primary PCI because of a high risk of catheter‑related thrombosis. ESC Class III, Level A. [29][31]

Fibrinolytic Therapy – When Primary PCI Cannot Be Performed Within 120 min

• If primary PCI cannot be achieved within 120 minutes of STEMI diagnosis, administer fibrinolysis within 12 hours of symptom onset in patients without contraindications. ESC Class I, Level A. [29][30]31
• Initiate fibrinolysis as early as possible, preferably pre‑hospital; each minute of delay increases mortality. ESC Class I, Level A. [29][31]
• Use a fibrin‑specific agent (tenecteplase, alteplase, or reteplase). ESC recommendation. [29][31]
• Combine the fibrinolytic with aspirin (oral or IV). ESC recommendation. [29][31]
• Add clopidogrel 300 mg loading dose (75 mg if age > 75 years) to aspirin for dual antiplatelet therapy. ESC recommendation. [29][30]31
• Prefer enoxaparin (IV bolus followed by sub‑cutaneous dosing every 12 h) for anticoagulation; weight‑adjusted unfractionated heparin targeting aPTT 50–70 s is an acceptable alternative. ESC recommendation. [29][30]31
• Continue anticoagulation until revascularisation or up to 8 days of hospital stay. ESC recommendation. 31

Post‑Fibrinolysis (Pharmacoinvasive Strategy)

• Transfer all fibrinolysed patients immediately to a PCI‑capable centre after fibrinolytic administration. ESC recommendation. [29][31]
• Perform emergency angiography and PCI without delay if the patient develops heart failure, cardiogenic shock, haemodynamic or electrical instability. ESC recommendation. [29][31]
• Initiate rescue PCI immediately if fibrinolysis fails (≤ 50 % ST‑segment resolution at 60–90 min) or if instability occurs at any time. ESC recommendation. [29][31]
• In patients who are stable after successful fibrinolysis, schedule angiography and PCI of the infarct‑related artery between 2 and 24 hours post‑therapy. ESC recommendation. [29][31]

Adjunctive Pharmacotherapy (First 24 h)

Cardioprotective Medications

• Start high‑intensity statin therapy immediately (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) aiming for LDL‑C < 1.8 mmol/L (≈ 70 mg/dL) or ≥ 50 % reduction. ESC Class I, Level A. 31
• Begin an ACE inhibitor within the first 24 h in patients with heart failure, left‑ventricular ejection fraction < 40 %, diabetes, or anterior infarction; use an ARB (e.g., valsartan 40–80 mg twice daily) if ACE‑I is not tolerated. ESC recommendation. 31
• Initiate oral beta‑blocker in patients with heart failure and/or LVEF < 40 % unless contraindicated (e.g., metoprolol tartrate 25–50 mg twice daily or carvedilol 3.125–6.25 mg twice daily, titrated upward). ESC recommendation. 31
• Avoid intravenous beta‑blockers in the presence of hypotension, acute heart failure, high‑grade AV block, or severe bradycardia. ESC Class III, Level A. [29][31]

Antiplatelet and Anticoagulant Maintenance

• Continue dual antiplatelet therapy (aspirin 75–100 mg daily + ticagrelor 90 mg twice daily or prasugrel 10 mg daily) for 12 months unless bleeding risk is excessive. ESC Class I, Level A. [29][30]31
• Add a proton‑pump inhibitor in patients at high risk of gastrointestinal bleeding. ESC recommendation. 31

Special Clinical Situations

Cardiac Arrest with STEMI

• In successfully resuscitated cardiac‑arrest patients who show STEMI on post‑resuscitation ECG, proceed with primary PCI. ESC recommendation. [29][31]
• Initiate early targeted temperature management in resuscitated patients who remain unresponsive. ESC recommendation. [29][31]
• Do not use pre‑hospital cooling with large volumes of cold IV fluid immediately after return of spontaneous circulation. ESC recommendation. [29][31]

Late Presentation (> 48 h)

• Do not perform routine PCI of an infarct‑related artery that remains occluded more than 48 hours after STEMI onset in asymptomatic patients. ESC Class III, Level A. [29][31]

Early In‑hospital Evaluation

• Perform routine transthoracic echocardiography during the hospital stay to assess left‑ and right‑ventricular function, detect early mechanical complications (ventricular septal defect, papillary‑muscle rupture, free‑wall rupture), and rule out left‑ventricular thrombus. ESC recommendation. [29][31]
• Monitor patients for at least 24 hours after reperfusion therapy in a coronary‑care or intensive‑care unit. ESC recommendation. 30

Secondary Prevention Initiated During Hospitalisation

• Identify all smokers and provide repeated cessation counselling together with pharmacotherapy options (varenicline, bupropion, or nicotine‑replacement therapy). ESC recommendation. 29
• Enrol every patient in a structured cardiac‑rehabilitation programme before discharge. ESC recommendation. 29

Dose Adjustments in Special Populations

• Adjust dosages of pharmacologic strategies in patients with renal impairment, the elderly, and those on oral anticoagulants. ESC recommendation. [29][30]
• Provide intensified medical therapy for diabetic patients and for those who do not receive reperfusion, as guided by aggressive ESC recommendations. ESC recommendation. [29][30]

ECG Diagnosis of Anterolateral Myocardial Infarction

Diagnostic Criteria

• The American College of Cardiology defines anterolateral MI by the presence of new ST‑segment elevation ≥ 0.1 mV (1 mm) at the J point in ≥ two contiguous anterior or lateral leads (typically V3–V6, I, aVL), provided left‑ventricular hypertrophy or left‑bundle‑branch block are absent. 32

Lead‑Specific Voltage Thresholds

• In the precordial leads V2–V3, the required ST‑segment elevation is sex‑ and age‑specific: ≥ 0.25 mV for men < 40 years, ≥ 0.20 mV for men ≥ 40 years, and ≥ 0.15 mV for women. 32
• In all other relevant leads (V4–V6, I, aVL), an ST‑segment elevation of ≥ 0.1 mV in two contiguous leads satisfies the threshold. 32

Additional ECG Indicators of Ischemia

• New horizontal or down‑sloping ST‑segment depression ≥ 0.05 mV in two contiguous leads, and/or T‑wave inversion ≥ 0.1 mV together with a prominent R wave (R/S > 1), signify sub‑endocardial ischemia and warrant urgent evaluation even when classic ST‑elevation is absent. 32
• A reduction in precordial R‑wave amplitude in leads V3–V6 is indicative of extensive myocardial injury. 32

Timing and Serial ECG Acquisition

• The initial 12‑lead ECG should be obtained within 10 minutes of patient arrival and compared with any prior tracings; dynamic ST‑segment changes during recurrent symptoms confirm acute ischemia. 32
• If the first ECG is nondiagnostic but symptoms persist, repeat ECGs every 15–30 minutes or employ continuous 12‑lead monitoring when available. 32

Evidence‑Based Management of STEMI for Residents

Initial Assessment and Immediate Actions

• Activate the cardiac catheterization laboratory and transfer the patient directly to the cath lab, bypassing the emergency department, as the single most important action to reduce mortality – ESC STEMI guideline, Class I, Level A. 33
• Obtain a 12‑lead ECG within 10 minutes of arrival to confirm ST‑segment elevation (≥1 mm in two contiguous leads, or ≥2 mm in V2‑V3 for men, ≥1.5 mm for women) – ESC STEMI guideline, Class I, Level A. 33
• Give aspirin 162–325 mg chewed (or 75–100 mg IV) immediately unless active gastrointestinal bleeding or a severe aspirin allergy is present – ESC STEMI guideline, Class I, Level A. [33][34]
• Do not administer supplemental oxygen routinely; give oxygen only if SpO₂ < 90 % because routine use increases mortality – ESC STEMI guideline, Class III, Level A. 33
• Do not delay reperfusion while awaiting laboratory results – ESC STEMI guideline, Class I, Level A. 33

Reperfusion Strategy

Primary PCI

• Choose primary PCI when first‑medical‑contact‑to‑device time can be ≤90 min for direct presentations or ≤120 min after inter‑facility transfer – ESC STEMI guideline, Class I, Level A. [33][35]36
• Call the cath lab immediately upon STEMI diagnosis; do not wait for troponin results, cardiology consultation, or patient stabilization – ESC STEMI guideline, Class I, Level A. [33][35]
• Transfer the patient directly to the cath lab, bypassing the ED holding area and ICU – ESC STEMI guideline, Class I, Level A. [33][35]

Fibrinolysis

• If primary PCI cannot be performed within 120 min and symptom onset is ≤12 h, administer fibrinolytic therapy – ESC STEMI guideline, Class I, Level A. [33][35]34
• Every 30‑minute delay in fibrinolysis administration increases mortality by approximately 7.5 % – ESC STEMI guideline, Class I, Level A. [33][34]
• Use tenecteplase (weight‑based single bolus) as the preferred fibrinolytic because it is easier to dose than alteplase – ESC STEMI guideline, Class I, Level A. [33][35]34

Antiplatelet Therapy for Primary PCI

• Give ticagrelor 180 mg loading dose (preferred) before or during PCI – ESC STEMI guideline, Class I, Level A. [33][34]
• If ticagrelor is unavailable, give prasugrel 60 mg loading dose, but avoid in patients ≥75 years, weight < 60 kg, or with prior stroke/TIA – ESC STEMI guideline, Class I, Level A. [33][34]
• Use clopidogrel 600 mg only when both ticagrelor and prasugrel are contraindicated or unavailable – ESC STEMI guideline, Class IIa, Level B. [33][34]
• Continue dual antiplatelet therapy (aspirin 81 mg daily + ticagrelor 90 mg twice daily or prasugrel 10 mg daily) for 12 months – ESC STEMI guideline, Class I, Level A. [33][34]

Anticoagulation for Primary PCI

• Administer unfractionated heparin 70–100 U/kg IV bolus (target ACT 250–350 s) at the start of PCI – ESC STEMI guideline, Class I, Level A. [33][34]
• If the patient has not received prior subcutaneous enoxaparin, a 0.5 mg/kg IV bolus of enoxaparin is an acceptable alternative – ESC STEMI guideline, Class I, Level A. [33][34]
• Avoid fondaparinux for primary PCI because it is associated with catheter thrombosis – ESC STEMI guideline, Class III, Level A. [33][34]

Contraindications to Fibrinolysis (Circulation 2013)

• Absolute contraindications: prior intracranial hemorrhage, known structural cerebrovascular lesion, ischemic stroke within 3 months, suspected aortic dissection, active bleeding (excluding menstrual bleeding), significant closed‑head trauma within 3 months. – ESC STEMI guideline, Class III, Level A. 36
• Relative contraindications (risk‑benefit assessment): severe uncontrolled hypertension (SBP > 180 mmHg or DBP > 110 mmHg), chronic severe hypertension, ischemic stroke >3 months ago, traumatic CPR, major surgery within 3 weeks, recent internal bleeding (2–4 weeks), non‑compressible vascular puncture, pregnancy, active peptic ulcer, current anticoagulation with INR > 2–3. – ESC STEMI guideline, Class IIb, Level B. 36

Fibrinolysis Regimen

• Tenecteplase (weight‑based single bolus) + aspirin 162–325 mg + clopidogrel 300 mg (75 mg if age > 75 years) – ESC STEMI guideline, Class I, Level A. [33][35]34
• Post‑fibrinolysis anticoagulation: enoxaparin 30 mg IV bolus then 1 mg/kg subcutaneously every 12 h (preferred). – ESC STEMI guideline, Class I, Level A. [33][35]34
• If unfractionated heparin is used: 60 U/kg IV bolus (max 4000 U) then infusion 12 U/kg/h (max 1000 U/h) targeting aPTT 50–70 s. – ESC STEMI guideline, Class I, Level A. [33][35]34

Post‑Fibrinolysis Monitoring and Management

• Repeat ECG at 60–90 minutes to assess ST‑segment resolution – ESC STEMI guideline, Class I, Level A. [33][34]36
• Successful reperfusion: ≥50 % ST‑segment resolution + resolution of chest pain; schedule coronary angiography 2–24 h after fibrinolysis. – ESC STEMI guideline, Class I, Level A. [33][34]36
• Failed fibrinolysis: <50 % ST‑segment resolution at 90 min; perform rescue PCI immediately. – ESC STEMI guideline, Class I, Level A. [33][34]36
• Emergency PCI is required immediately if cardiogenic shock, pulmonary edema, hemodynamic instability, or ventricular arrhythmias develop after fibrinolysis – ESC STEMI guideline, Class I, Level A. [33][34]36
• All patients who receive fibrinolysis should be transferred promptly to a PCI‑capable center, regardless of reperfusion success – ESC STEMI guideline, Class I, Level A. [33][34]36

Early Adjunctive Therapies

• High‑intensity statin therapy should be started immediately (atorvastatin 80 mg or rosuvastatin 40 mg daily) with a target LDL < 70 mg/dL – ESC STEMI guideline, Class I, Level A. [33][34]
• Begin an ACE inhibitor within 24 hours in patients with heart failure, LVEF < 40 %, diabetes, or anterior MI – ESC STEMI guideline, Class I, Level A. [33][34]
• Start an oral beta‑blocker within 24 hours in patients with LVEF < 40 % or heart failure – ESC STEMI guideline, Class I, Level A. [33][34]
• Prescribe a proton‑pump inhibitor (e.g., omeprazole 20 mg daily) for all patients on dual antiplatelet therapy to reduce gastrointestinal bleeding risk – ESC STEMI guideline, Class IIa, Level B. [33][34]

Critical Pitfalls to Avoid

• Do not give intravenous beta‑blockers in the acute phase when the patient has hypotension (SBP < 100 mmHg), heart failure, high‑grade AV block, or heart rate < 60 bpm, as this increases mortality – ESC STEMI guideline, Class III, Level A. [33][34]
• Do not delay reperfusion to obtain echocardiography, cardiology consultation, or family consent – ESC STEMI guideline, Class III, Level A. 33
• Do not perform PCI on a chronically occluded artery (>48 h) in asymptomatic patients; no outcome benefit has been demonstrated – ESC STEMI guideline, Class III, Level A. [33][34]
• Do not use prasugrel in patients ≥75 years or with prior stroke/TIA; use ticagrelor instead – ESC STEMI guideline, Class III, Level A. [33][34]

Special Situations

• Cardiac arrest with STEMI: proceed with primary PCI in successfully resuscitated patients; initiate targeted temperature management (32–36 °C for 24 h) if the patient remains comatose; avoid large‑volume cold IV fluids for pre‑hospital cooling. – ESC STEMI guideline, Class I, Level A. [33][34]
• Post‑fibrinolysis echocardiography within 24 hours to assess left‑ventricular function, wall‑motion abnormalities, mechanical complications, and left‑ventricular thrombus. – ESC STEMI guideline, Class I, Level A. [33][34]
• Enroll all patients in cardiac rehabilitation before discharge; participation reduces 1‑year mortality by approximately 25 % – ESC STEMI guideline, Class I, Level A. [33][34]

Documentation and Quality Metrics (Circulation 2013)

• Record exact times of symptom onset, first medical contact, ECG acquisition, fibrinolytic administration (if given), and device activation (if PCI performed); these are core quality metrics – ESC STEMI guideline, Class I, Level A. 36

Immediate Reperfusion and Early Management of Anterior STEMI Restoring Sinus Rhythm after 2 Hours

Primary Percutaneous Coronary Intervention (PCI)

• The American College of Cardiology recommends that patients with anterior STEMI who revert to sinus rhythm after 2 hours still require immediate definitive reperfusion; the rhythm change does not alter the indication for primary PCI or fibrinolysis. 37, 38
• The American College of Cardiology recommends direct transfer to the cardiac catheterization laboratory, bypassing the emergency department, to achieve a first‑medical‑contact‑to‑device time ≤ 120 minutes. 37, 38
• The American College of Cardiology recommends administering a potent P2Y12 inhibitor before or during PCI—ticagrelor 180 mg loading dose preferred; prasugrel 60 mg as an alternative unless age ≥ 75 years or prior stroke/TIA; clopidogrel 600 mg only if the others are unavailable. 37, 38
• The American College of Cardiology recommends unfractionated heparin 70–100 U/kg IV bolus (target ACT 250–350 s) or enoxaparin 0.5 mg/kg IV bolus for intraprocedural anticoagulation. 37, 38
• The American College of Cardiology states that fondaparinux is absolutely contraindicated for primary PCI because of a high risk of catheter‑related thrombosis. 37, 38

Fibrinolytic Therapy (When Primary PCI > 120 min)

• The American College of Cardiology advises that if primary PCI cannot be performed within 120 minutes of STEMI diagnosis, fibrinolytic therapy should be given within 12 hours of symptom onset to patients without contraindications. 39, 40, 37
• The American College of Cardiology recommends using a fibrin‑specific agent (tenecteplase, alteplase, or reteplase) for fibrinolysis. 37, 38
• The American College of Cardiology recommends adding clopidogrel 300 mg loading dose (75 mg if age > 75 years) to aspirin for dual antiplatelet therapy when fibrinolysis is administered. 37, 38
• The American College of Cardiology recommends enoxaparin (30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 h) for anticoagulation; alternatively, weight‑adjusted unfractionated heparin (60 U/kg bolus then infusion targeting aPTT 50–70 s) may be used. 37, 38

Post‑Fibrinolysis Management

• The American College of Cardiology advises immediate transfer of all patients who have received fibrinolysis to a PCI‑capable center after the thrombolytic agent is given. 37, 38
• The American College of Cardiology recommends urgent angiography and PCI without delay for patients who develop heart failure, cardiogenic shock, hemodynamic instability, or electrical instability after fibrinolysis. 37, 38
• The American College of Cardiology advises initiating rescue PCI promptly if fibrinolysis fails (≤ 50 % ST‑segment resolution at 60–90 min) or if instability occurs at any time. 37, 38
• The American College of Cardiology recommends scheduling angiography and PCI of the infarct‑related artery between 2 and 24 hours after successful fibrinolysis in stable patients. 37, 38

Adjunctive Pharmacologic Therapy (First 24 Hours)

Cardioprotective Medications

• The American College of Cardiology recommends initiating high‑intensity statin therapy immediately (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) with a target LDL‑C < 1.8 mmol/L (≈ 70 mg/dL) or ≥ 50 % reduction. 41, 37
• The American College of Cardiology recommends starting an ACE inhibitor within 24 hours in patients with heart failure, left‑ventricular ejection fraction < 40 %, diabetes, or anterior infarction; an ARB may be used if ACE inhibition is not tolerated. 41, 37
• The American College of Cardiology recommends initiating an oral beta‑blocker in patients with heart failure and/or LVEF < 40 % unless contraindicated. 41, 37
• The American College of Cardiology advises avoiding intravenous beta‑blockers in patients with hypotension, acute heart failure, high‑grade AV block, or severe bradycardia. 41, 37

Antiplatelet Therapy

• The American College of Cardiology recommends continuing dual antiplatelet therapy (aspirin 75–100 mg daily + ticagrelor 90 mg twice daily or prasugrel 10 mg daily) for 12 months unless the patient has an excessive bleeding risk. 37, 38

Practices to Avoid

• The American College of Cardiology advises against performing PCI on chronically occluded arteries (> 48 hours) in asymptomatic patients, as no outcome benefit has been demonstrated. 37, 38
• The American College of Cardiology reiterates that fondaparinux must not be used as anticoagulation for primary PCI. 37, 38

Initial In‑Hospital Evaluation

• The American College of Cardiology recommends routine transthoracic echocardiography during hospitalization to assess left‑ and right‑ventricular function, detect early mechanical complications (ventricular septal defect, papillary‑muscle rupture, free‑wall rupture), and exclude left‑ventricular thrombus. 37, 38

Acute Coronary Syndrome – Immediate Management Guidelines

Initial Assessment and Early Therapy

• Obtain a 12‑lead ECG within 10 minutes of arrival and give aspirin 75–100 mg orally or intravenously immediately, unless active bleeding or severe allergy is present. (ACC guideline) 42
• Initiate continuous cardiac monitoring with defibrillator capability to detect life‑threatening arrhythmias. (ACC guideline) 42
• Provide supplemental oxygen only when peripheral SpO₂ < 90 %; routine oxygen does not improve outcomes and may cause harm. (ACC guideline) 42

Reperfusion Strategy

Primary Percutaneous Coronary Intervention (PCI)

• Primary PCI is the default reperfusion method when first‑medical‑contact‑to‑device time can be ≤ 90–120 minutes. (ACC guideline) 42
• Transfer STEMI patients directly to the cardiac catheterization laboratory, bypassing the emergency department and intensive‑care unit. (ACC guideline) 42
• Cath‑lab activation must be available 24 hours/7 days for all PCI‑capable centers. (ACC guideline) 42

Fibrinolytic Therapy (when PCI > 120 min)

• If primary PCI cannot be performed within 120 minutes, administer fibrin‑specific fibrinolytic therapy (tenecteplase, alteplase, or reteplase) within 12 hours of symptom onset in patients without contraindications. (ACC guideline) 42
• Each minute of delay in fibrinolysis increases mortality; therefore, initiate therapy as early as possible, preferably in the pre‑hospital setting. (ACC guideline) 42

Antiplatelet Therapy

For Primary PCI

• Give a potent P2Y12 inhibitor before or at the time of PCI: ticagrelor 180 mg loading dose is preferred; prasugrel 60 mg is an alternative but contraindicated in patients ≥ 75 years or with prior stroke/TIA; clopidogrel 600 mg only if the former agents are unavailable. (ACC & CCS guidelines) 42, 43, 44
• Continue dual antiplatelet therapy (aspirin 75–100 mg daily + ticagrelor 90 mg twice daily or prasugrel 10 mg daily) for 12 months unless bleeding risk is excessive. (ACC & CCS guidelines) 42, 43

After Fibrinolysis

• Add clopidogrel 300 mg loading dose (75 mg if age > 75 years) to aspirin for dual antiplatelet therapy. (ACC guideline) 42, 44

For NSTEMI

• In patients scheduled for an invasive strategy with angiography > 24 hours, upstream clopidogrel or ticagrelor may be considered. (ACC guideline) 42
• For an immediate invasive strategy (< 24 hours), defer P2Y12 inhibitor administration until coronary anatomy is defined at angiography. (ACC & AHA guideline) 42, 45

Anticoagulation

Primary PCI

• Use unfractionated heparin 70–100 U/kg bolus (target ACT 250–350 seconds) or enoxaparin 0.5 mg/kg IV bolus for intraprocedural anticoagulation. (ACC guideline) 42
• Fondaparinux is absolutely contraindicated for primary PCI because of a high risk of catheter‑related thrombosis. (AHA/Circulation guideline) 46, 42

Fibrinolysis

• Prefer enoxaparin 30 mg IV bolus followed by 1 mg/kg subcutaneously every 12 hours; weight‑adjusted unfractionated heparin (60 U/kg bolus then infusion targeting aPTT 50–70 seconds) is an acceptable alternative. (AHA/Circulation & ACC guidelines) 46, 42
• Continue anticoagulation until revascularization or for the duration of the hospital stay, up to 8 days. (AHA/Circulation & ACC guidelines) 46, 45

NSTEMI (Conservative or Delayed Invasive Strategy)

• For a planned conservative approach, fondaparinux or enoxaparin are reasonable alternatives to unfractionated heparin. (AHA/Circulation guideline) 46
• For a planned invasive approach, either enoxaparin or unfractionated heparin are reasonable choices. (AHA/Circulation guideline) 46

Post‑Fibrinolysis Management

• Transfer all fibrinolyzed patients immediately to a PCI‑capable center after fibrinolytic administration. (ACC guideline) 42
• Perform emergency angiography and PCI without delay if the patient develops heart failure, cardiogenic shock, hemodynamic instability, or electrical instability. (ACC guideline) 42
• Initiate rescue PCI immediately if fibrinolysis fails (≤ 50 % ST‑segment resolution at 60–90 minutes). (ACC guideline) 42
• In stable patients after successful fibrinolysis, schedule angiography and PCI of the infarct‑related artery between 2 and 24 hours post‑therapy. (ACC guideline) 42

Adjunctive Pharmacotherapy (First 24 Hours)

Cardioprotective Medications

• Start high‑intensity statin therapy immediately (atorvastatin 80 mg daily or rosuvastatin 40 mg daily) aiming for LDL‑C < 1.8 mmol/L (≈ 70 mg/dL) or ≥ 50 % reduction. (ACC guideline) 42
• Initiate an ACE inhibitor within the first 24 hours in patients with heart failure, left‑ventricular ejection fraction < 40 %, diabetes, or anterior MI; use an ARB if ACE inhibition is not tolerated. (ACC guideline) 42
• Begin oral beta‑blocker therapy in patients with heart failure and/or LVEF < 40 % unless contraindicated. (ACC guideline) 42
• Avoid intravenous beta‑blockers in the presence of hypotension, acute heart failure, high‑grade AV block, or severe bradycardia. (AHA/Circulation & ACC guidelines) 46, 42

Gastro‑protective Therapy

• Add a proton‑pump inhibitor in patients at high risk of gastrointestinal bleeding. (ACC guideline) 42

Bleeding‑Risk Mitigation

• Transition to ticagrelor monotherapy ≥ 1 month after PCI in patients who have tolerated dual antiplatelet therapy, to reduce bleeding risk. (ACC guideline) 42
• For patients requiring long‑term anticoagulation, discontinue aspirin 1–4 weeks after PCI while continuing a P2Y12 inhibitor (preferably clopidogrel). (ACC guideline) 42

Special Clinical Situations

Cardiogenic Shock

• Emergency revascularization (PCI or CABG) is recommended in suitable patients with cardiogenic shock after STEMI, irrespective of time elapsed since MI onset. (ACC guideline) 42
• Use of a microaxial flow pump (e.g., Impella) is reasonable in selected shock patients to reduce mortality, acknowledging higher rates of bleeding, limb ischemia, and renal failure; careful vascular‑access management and weaning are essential. (ACC guideline) 42

Cardiac Arrest with STEMI

• Pursue primary PCI in patients resuscitated from cardiac arrest who show STEMI on ECG. (ACC guideline) 42
• Initiate targeted temperature management early in resuscitated patients who remain unresponsive. (ACC guideline) 42
• Do not use pre‑hospital cooling with large volumes of cold IV fluid immediately after return of spontaneous circulation. (AHA/Circulation & ACC guidelines) 46, 42

Anemia

• Red‑blood‑cell transfusion to maintain a hemoglobin of 10 g/dL may be reasonable in ACS patients with acute or chronic anemia who are not actively bleeding. (ACC guideline) 42

Critical Pitfalls to Avoid

• Do not postpone reperfusion therapy for routine echocardiography or other non‑essential testing in clear STEMI cases. (ACC guideline) 42
• Do not perform routine PCI of an occluded infarct‑related artery beyond 48 hours after STEMI onset in asymptomatic patients. (ACC guideline) 42
• Fondaparinux must not be used as anticoagulation for primary PCI. (AHA/Circulation & ACC guidelines) 46, 42
• NSAIDs other than aspirin should not be administered and may be harmful in patients with suspected ACS. (AHA/Circulation guideline) 46

Secondary Prevention

• Enroll all patients in a structured cardiac rehabilitation program; home‑based programs are acceptable for those unable or unwilling to attend. (ACC guideline) 42
• Obtain a fasting lipid panel 4–8 weeks after initiating or adjusting lipid‑lowering therapy. (ACC guideline) 42

ECG Diagnosis and Contraindications for Fibrinolysis in STEMI

ECG Acquisition and Interpretation

• Obtain a 12‑lead electrocardiogram within 10 minutes of patient arrival and confirm ST‑segment elevation ≥ 1 mm in two contiguous leads (or ≥ 2 mm in V2–V3 for men, ≥ 1.5 mm for women) before initiating reperfusion therapy. This rapid ECG is required to diagnose STEMI and guide immediate treatment decisions. 47

Absolute Contraindications to Fibrinolytic Therapy

• Do not administer fibrinolysis to patients with a history of intracranial hemorrhage at any time. 47
• Do not administer fibrinolysis to patients with a known structural cerebrovascular lesion (e.g., arteriovenous malformation, aneurysm). 47
• Do not administer fibrinolysis to patients who have experienced an ischemic stroke within the preceding 3 months. 47
• Do not administer fibrinolysis to patients with suspected aortic dissection. 47
• Do not administer fibrinolysis to patients with active bleeding (excluding menstrual bleeding). 47
• Do not administer fibrinolysis to patients who have suffered significant closed‑head or facial trauma within the preceding 3 months. 47